Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (693)	1/2/1999 7:21:00 AM
From: Henry Niman	Respond to of 1906

A Eureka Alert was issued on the Science paper on Epogen regulation. It is linked to the Transcription Regulation table under New Therapeutics at biocognizance.com The summary gives a clear explanation of the system.

To: Mike McFarland who wrote (693)	1/2/1999 7:26:00 AM
From: Henry Niman	Respond to of 1906

Mike, I haven't had a chance to read the Science article in full, but a summary is linked to the Transcription Regulation table. The Yahoo poster wrote that in primates, the cassette fell apart at 90 days, indicating that more work needs to be done. However, the results were quite impressive at 30 and 60 days in the primate study.

To: Mike McFarland who wrote (693)	1/2/1999 7:32:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 1906

Mike, AMGN added some sugars to Epogen and called in NESP. They claimed that the modified protein was a new protein and not covered under the JNJ licensing deal. Details are linked to the Biotech Boom table at biocognizance.com